1. Home
  2. IFRX vs AMWL Comparison

IFRX vs AMWL Comparison

Compare IFRX & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • AMWL
  • Stock Information
  • Founded
  • IFRX 2007
  • AMWL 2006
  • Country
  • IFRX Germany
  • AMWL United States
  • Employees
  • IFRX N/A
  • AMWL N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • AMWL Retail: Computer Software & Peripheral Equipment
  • Sector
  • IFRX Health Care
  • AMWL Technology
  • Exchange
  • IFRX Nasdaq
  • AMWL Nasdaq
  • Market Cap
  • IFRX 143.7M
  • AMWL 146.3M
  • IPO Year
  • IFRX 2017
  • AMWL 2020
  • Fundamental
  • Price
  • IFRX $2.47
  • AMWL $10.98
  • Analyst Decision
  • IFRX Strong Buy
  • AMWL Hold
  • Analyst Count
  • IFRX 1
  • AMWL 4
  • Target Price
  • IFRX $8.00
  • AMWL $12.50
  • AVG Volume (30 Days)
  • IFRX 174.5K
  • AMWL 60.7K
  • Earning Date
  • IFRX 11-08-2024
  • AMWL 02-12-2025
  • Dividend Yield
  • IFRX N/A
  • AMWL N/A
  • EPS Growth
  • IFRX N/A
  • AMWL N/A
  • EPS
  • IFRX N/A
  • AMWL N/A
  • Revenue
  • IFRX $187,930.00
  • AMWL $254,035,000.00
  • Revenue This Year
  • IFRX $392.79
  • AMWL N/A
  • Revenue Next Year
  • IFRX $156.76
  • AMWL $24.96
  • P/E Ratio
  • IFRX N/A
  • AMWL N/A
  • Revenue Growth
  • IFRX 177.12
  • AMWL N/A
  • 52 Week Low
  • IFRX $1.17
  • AMWL $5.00
  • 52 Week High
  • IFRX $2.82
  • AMWL $29.00
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 53.59
  • AMWL 71.54
  • Support Level
  • IFRX $2.16
  • AMWL $7.02
  • Resistance Level
  • IFRX $2.65
  • AMWL $8.83
  • Average True Range (ATR)
  • IFRX 0.23
  • AMWL 0.66
  • MACD
  • IFRX -0.01
  • AMWL 0.39
  • Stochastic Oscillator
  • IFRX 52.54
  • AMWL 91.25

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About AMWL American Well Corporation

American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.

Share on Social Networks: